The company is a world-leading, technology-driven CDMO (Pharmaceutical Contract Customized R&D and Production) one-stop integrated service provider. It provides one-stop CMC services for the entire life cycle of drugs, efficient and high-quality R&D and production services for over 1,100 customers around the world, and accelerates clinical research and commercial application of innovative drugs. It is the world's leading innovative drug ingredient CDMO, China's largest commercial-stage chemical drug CDMO company, and has achieved “A+H” dual market listing. The company is a world-leading, technology-driven one-stop integrated service provider for pharmaceutical outsourcing, providing one-stop service for domestic and foreign pharmaceutical companies and biotechnology companies throughout the life cycle of drugs. The main products are small molecule CDMO services, chemical macromolecule CDMO sector, pharmaceutical CDMO section, clinical CRO section, biomacromolecule CDMO section, technology export section, and synthetic biotechnology sector. In 2019, the company won the “2018 Best Partner for the Transformation and Upgrading of Chinese Pharmaceutical Enterprises”. A total of 6 award-winning companies/organizations were selected in this selection. As the only pharmaceutical CDMO company on the list, the company received awards through various levels of screening with excellent quality and service, good reputation and reputation — this is also another time for the company to win this award. It won two awards, “China's Top 100 Pharmaceutical Industry” and “China's Top 20 Pharmaceutical Outsourcing Companies” in the “2018 China Pharmaceutical Industry Most Influential List” issued by the Pharmaceutical Industry Chamber of Commerce of the All-China Federation of Industry and Commerce, fully demonstrating the company's strong competitiveness and strong growth as an industry benchmark.